Antibody Drug Conjugate Market (7th Edition), 2023-2035: Distribution by Target Disease Indication (Breast Cancer, B-cell Lymphoma, Lung Cancer, Multiple Myeloma, Acute Lymphoblastic Leukemia, Gastric Cancer, Renal Cancer, Cervical Cancer and Other Target Disease Indications), Therapeutic Area (Hematological Cancer and Solid Tumor), Linker (Valine-Citrulline, Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate, Tetrapeptide-based Linker, Maleimide, Maleimidocaproyl, Valine-Alanine, Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (AcBut) and Other Linkers), Payload (Monomethyl Auristatin E, DM1, Duocarmycin, SN-38 / Irinotecan, Monomethyl Auristatin F, SG3199, Ozogamicin, DM4 and Other Payloads), Target Antigens (HER-2 (ERBB2), CD79b, Trop-2, BCMA (TNFRSF17 / BCM), CD19, CD22, Tissue Factor, CD30, CEACAM5, Nectin 4 and Others) And Key Geographical Regions (North America (US, Canada), Europe (Germany, UK, France, Italy, Spain), and Asia-Pacific (China, Australia, Japan)): Industry Trends and Global Forecasts
The global antibody drug conjugate market is expected to reach USD 7.72 billion by 2023 and is anticipated to grow at a CAGR of 9.63% during the forecast period 2023-2035
Antibody drug conjugates (ADCs) are a class of engineered therapeutics that combine monoclonal antibodies with potent cytotoxic payloads through specialized chemical linkers. These innovations have propelled ADCs into the spotlight as potent treatments for a broad spectrum of conditions, including solid tumors and hematological malignancies. This is owing to advancements in antibody engineering, which facilitate site-specific conjugation and improve pharmacokinetic and pharmacodynamic characteristics. Presently, the USFDA has approved 14 antibody-drug conjugates for therapeutic application, such as ado-trastuzumab emtansine (Kadcyla), brentuximab vedotin (Adcetris), inotuzumab ozogamicin (Besponsa), gemtuzumab ozogamicin (Mylotarg), and others.
The notable success of ADC therapeutics can be attributed to their exceptional tumor selectivity and potent cell-killing abilities, while effectively limiting off-target toxicities. Ongoing advancements in this field are fueled by promising outcomes from previous clinical trials, particularly focusing on various solid tumor types. With continued innovation, strong financial backing from investors, and encouraging clinical trial results, the market for antibody drug conjugates is poised for significant expansion in the projected period.
Report Coverage
Antibody drug conjugates (ADCs) are a class of engineered therapeutics that combine monoclonal antibodies with potent cytotoxic payloads through specialized chemical linkers. These innovations have propelled ADCs into the spotlight as potent treatments for a broad spectrum of conditions, including solid tumors and hematological malignancies. This is owing to advancements in antibody engineering, which facilitate site-specific conjugation and improve pharmacokinetic and pharmacodynamic characteristics. Presently, the USFDA has approved 14 antibody-drug conjugates for therapeutic application, such as ado-trastuzumab emtansine (Kadcyla), brentuximab vedotin (Adcetris), inotuzumab ozogamicin (Besponsa), gemtuzumab ozogamicin (Mylotarg), and others.
The notable success of ADC therapeutics can be attributed to their exceptional tumor selectivity and potent cell-killing abilities, while effectively limiting off-target toxicities. Ongoing advancements in this field are fueled by promising outcomes from previous clinical trials, particularly focusing on various solid tumor types. With continued innovation, strong financial backing from investors, and encouraging clinical trial results, the market for antibody drug conjugates is poised for significant expansion in the projected period.
Report Coverage
- The report conducts an analysis of the antibody drug conjugates market, focusing on target disease indications, therapeutic areas, linkers, payloads, target antigens, and key geographical regions.
- Examination of market growth factors—drivers, restraints, opportunities, and challenges—to understand their impact on the industry's development.
- Evaluation of potential advantages and obstacles within the market, providing insights into the competitive landscape for leading market players.
- Revenue forecasting for market segments across three major regions to gauge market potential and growth prospects.
- Concise presentation of research insights to encapsulate the current status and future trajectory of the antibody drug conjugate market.
- Introduction to antibody drug conjugates, encompassing their historical background, structural aspects, advantages, and pharmacokinetic properties.
- Comprehensive assessment of the market landscape, analyzing nearly 400 antibody drug conjugates in terms of their developmental status, disease indications, therapeutic areas, treatment lines, dosing frequencies, therapy types, target antigens, antibody types, payloads, linkers, and developer information.
- Insightful competitiveness analysis of biological targets using three-dimensional bubble representations and six-dimensional spider-web analysis, evaluating parameters such as development stages, therapy numbers, and indications.
- Detailed profiles of leading antibody drug conjugate companies based on 2022 sales revenue, including company overviews, financial information (if available), product portfolios, recent developments, and future outlooks.
- In-depth profiles of marketed ADC therapeutics, detailing their mechanisms of action, target antigens, linkers, payloads, therapy types, and sales data (if applicable).
- Analysis of completed, ongoing, and planned clinical studies on ADCs, covering parameters like trial registration, phases, patient populations, sponsors, study designs, industry players, non-industry participants, and geographical regions.
- Assessment of key opinion leaders (KOLs) involved in ADC-related clinical trials, considering KOL types, qualifications, affiliations, geographical locations, and prominent figures based on proprietary and third-party criteria.
- Analysis of therapeutics in combination with ADCs across various indications and their potential evolution.
- Detailed examination of partnerships formed in the ADC industry since 2014, focusing on partnership types, purposes, partner types, active players, and regional distributions.
- Examination of funding and investments in the ADC domain since 2014, covering financing types, amounts invested, leading companies, investors, and geographical analyses.
- In-depth analysis of ADC-related patents, including types, publication years, geographical locations, player types, assigned CPC symbols, organizations, and valuation assessments.
- Study of grants awarded to research institutes engaged in ADC-related research since 2016, considering grant details, funding institutes, support periods, grant purposes, popular NIH departments, recipient organizations, and key regions.
- Discussion on commercialization strategies pre, during, and post-launch of ADC products, featuring a framework outlining necessary steps and guidelines.
- Analysis of promotional strategies employed by developers of marketed ADC products, examining approaches used for products like Adcetris, Besponsa, Enhertu, etc.
- Success protocol analysis of recently approved ADC therapeutics based on parameters such as dosing frequency, efficacy, exclusivity, competition, prevalence, pricing, therapy type, and developer competition
- Overview of conjugation and linker technologies utilized in ADC development.
- Analysis of non-clinical data supporting First-In-Human (FIH) dose selection in ADCs, including findings from animal studies and methods for estimating FIH doses.
- Discussion on factors influencing ADC pricing, presenting different pricing approaches for pharmaceutical companies in determining prices for their lead therapy candidates.
- Case studies on ADC manufacturing challenges and contract service providers, alongside companion diagnostic companies offering tests for ADC treatment decisions.
- Exploration of industry evolution through SWOT analysis, assessing trends, drivers, challenges, and their relative impact on the overall industry landscape.
- ADC Therapeutics
- Astellas Pharma
- AstraZeneca
- Byondis
- Daiichi Sankyo
- Genentech
- Gilead Sciences
- ImmunoGen
- Pfizer
- RemeGen
1. PREFACE
1.1. Antibody Drug Conjugate Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Antibody Drug Conjugates
3.3.1. History of Antibody Drug Conjugates
3.3.2. Difference between Small Molecule Drugs, Monoclonal Antibody Therapies and Antibody Drug Conjugates
3.3.3. Components of Antibody Drug Conjugates
3.3.3.1. Antibody
3.3.3.2. Cytotoxin
3.3.3.3. Linker
3.3.4. Advantages of Antibody Drug Conjugates Therapeutics over Traditional Therapeutics
3.3.5. Pharmacokinetic Properties of Antibody-Drug Conjugates
3.3.5.1. Absorption
3.3.5.2. Distribution
3.3.5.3. Metabolism and Elimination
3.4. Concluding Remarks
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Antibody Drug Conjugates: Therapies Pipeline
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Target Disease Indication
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Line of Treatment
4.2.5. Analysis by Dosing Frequency
4.2.6. Analysis by Type of Therapy
4.2.7. Analysis by Target Antigen
4.2.8. Analysis by Antibody Isotype
4.2.9. Analysis by Payload / Cytotoxin / Warhead
4.2.10. Analysis by Type of Payload
4.2.11. Analysis by Linker
4.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)
4.3. Antibody Drug Conjugate: List of Therapy Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company size and Location of Headquarters
4.3.5. Most Active Players: Analysis by Number of Therapies
5. TARGET COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Parameters
5.3. Methodology
5.4. Target Competitiveness Analysis: Key Targets of Antibody Drug Conjugates
5.4.1. Three-Dimensional Bubble Analysis
5.4.1.1. Targets of Approved / Marketed Drugs
5.4.1.2. Targets of Phase III Drugs
5.4.1.3. Targets of Phase II Drugs
5.4.1.4. Targets of Phase I Drugs
5.4.1.5. Targets of Pre-Clinical Drugs
5.4.2. Six-Dimensional Spider Web Analysis
6. COMPANY AND DRUG PROFILES
6.1. Chapter Overview
6.2. ADC Therapeutics
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Pipeline Overview
6.2.3.1. Zynlonta
6.2.4. Recent Developments and Future Outlook
6.3. Astellas Pharma
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Pipeline Overview
6.3.3.1. Padcev
6.3.4. Recent Developments and Future Outlook
6.4. AstraZeneca
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Pipeline Overview
6.4.3.1. Enhertu
6.4.4. Recent Developments and Future Outlook
6.5. Byondis
6.5.1. Company Overview
6.5.2. Financial Information
6.5.2.1. Pipeline Overview
6.5.3. Trastuzumab duocarmazine
6.5.4. Recent Developments and Future Outlook
6.6. Daiichi Sankyo
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Pipeline Overview
6.6.3.1. Enhertu
6.6.4. Recent Developments and Future Outlook
6.7. Genentech (Subsidiary of Roche)
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Pipeline Overview
6.7.3.1. Kadcyla
6.7.3.2. Polivy
6.7.4. Recent Developments and Future Outlook
6.8. Gilead Sciences
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Pipeline Overview
6.8.3.1. Trodelvy
6.8.4. Recent Developments and Future Outlook
6.9. ImmunoGen
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Pipeline Overview
6.9.3.1. Elahere
6.9.4. Recent Developments and Future Outlook
6.10. Pfizer
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Pipeline Overview
6.10.3.1. Mylotarg
6.10.3.2. Besponsa
6.10.4. Recent Developments and Future Outlook
6.11. RemeGen
6.11.1. Company Overview
6.11.2. Financial Information
6.11.3. Pipeline Overview
6.11.3.1. Disitamab vedotin
6.11.4. Recent Developments and Future Outlook
6.12. Seagen
6.12.1. Company Overview
6.12.2. Financial Information
6.12.3. Pipeline Overview
6.12.3.1. Adcetris
6.12.3.2. Padcev
6.12.3.3. Tivdak
6.12.4. Recent Developments and Future Outlook
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Antibody Drug Conjugates: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Status
7.3.3. Analysis by Trial Status and Patients Enrolled
7.3.4. Analysis by Trial Registration Year and Trial Status
7.3.5. Analysis by Trial Registration Year and Patients Enrolled
7.3.6. Analysis by Trial Phase
7.3.7. Analysis by Trial Phase and Patients Enrolled
7.3.8. Analysis by Type of Sponsor / Collaborator
7.3.9. Analysis by Target Population
7.3.10. Analysis by Study Design
7.3.11. Most Active Industry Players: Analysis by Number of Trials
7.3.12. Most Active Non-Industry Players: Analysis by Number of Trials
7.3.13. Analysis of Clinical Trials by Geography
7.3.14. Analysis of Patients Enrolled by Geography
8. KEY OPINION LEADERS
8.1. Chapter Overview
8.2. Assumption and Key Parameters
8.3. Methodology
8.4. Antibody Drug Conjugates: Key Opinion Leaders
8.4.1. Analysis by Type of KOLs
8.4.2. Analysis by Qualification
8.4.3. Analysis by Affiliated Organization
8.4.4. Analysis by Type of Organization
8.4.5. Analysis by Geographical Location of KOLs
8.4.6. Most Prominent KOLs: Analysis by KOLs Activeness, Expertise and Strength
8.4.7. Most Prominent KOLs: Analysis by RA score
8.4.8. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
9. COMBINATION THERAPIES
9.1. Chapter Overview
9.2. Combination Therapies: History of Development
9.3. Combination Therapies: FDA Guidelines
9.3.1. Combination of Marketed Drugs
9.3.2. Combinations of Marketed Drugs with New Molecular Entities
9.3.3. Combination of New Molecular Entities
9.4. Combination Therapies: Antibody Drug Conjugates
9.4.1. Completed / Ongoing Clinical Studies of Antibody Drug Conjugates
9.4.1.1. Analysis by Type of Therapy
9.4.2. Completed / Ongoing Clinical Studies of Antibody Drug Conjugate-based Combination Therapies
9.4.2.1. Analysis by Phase of Development
9.4.2.2. Analysis by Trial Status
9.4.2.3. Analysis by Target Disease Indication
9.4.2.4. Most Popular Antibody Drug Conjugates Used in Combination Therapies: Analysis by Number of Trials
9.4.2.5. Most Popular Drug Class Used in Combination Therapies: Analysis by Number of Trials
9.4.2.6. Analysis by Target Disease Indication and Drug Class Used in Antibody Drug Conjugate-based Combination Therapies
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Antibody Drug Conjugates: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Purpose of Partnership
10.3.5. Analysis by Type of Partner
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.3.7. Analysis by Geography
10.3.7.1. International and Local Agreements
10.3.7.2. Intercontinental and Intracontinental Agreements
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Antibody Drug Conjugates: List of Funding and Investment Analysis
11.3.1. Analysis by Year of Funding
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Year and Type of Funding
11.3.5. Analysis by Type of Investor
11.3.6. Analysis by Amount Invested by Geography
11.3.6.1. Analysis by Region
11.3.6.2. Analysis by Country
11.3.7. Most Active Players: Analysis by Number of Funding Instances
11.3.8. Most Active Players: Analysis by Amount Invested
11.3.9. Key Investors: Analysis by Number of Funding Instances
12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Antibody Drug Conjugates: Patent Analysis
12.3.1. Analysis by Patent Publication Year
12.3.2. Analysis by Patent Application Year
12.3.3. Analysis by Annual Number of Granted Patents and Patent Applications
12.3.4. Analysis by Patent Jurisdiction
12.3.5. Analysis by CPC Symbols
12.3.6. Analysis by Type of Applicant
12.3.7. Leading Industry Players: Analysis by Number of Patents
12.3.8. Leading Non-Industry Players: Analysis by Number of Patents
12.3.9. Leading Individual Assignees: Analysis by Number of Patents
12.4. Antibody Drug Conjugate: Patent Benchmarking Analysis
12.4.1. Analysis by Patent Characteristics
12.5. Antibody Drug Conjugate: Patent Valuation
12.6. Leading Patents by Number of Citations
13. ACADEMIC GRANTS ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Antibody Drug Conjugates: Grants Analysis
13.3.1. Analysis by Year of Grant Award
13.3.2. Analysis by Amount Awarded
13.3.3. Analysis by Funding Institute
13.3.4. Analysis by Support Period
13.3.5. Analysis by Type of Grant Application
13.3.6. Analysis by Purpose of Grant Award
13.3.7. Analysis by Activity Code
13.3.8. Analysis by Study Section Involved
13.3.9. Popular NIH Departments: Analysis by Number of Grants
13.3.9.1. Prominent Program Officers: Analysis by Number of Grants
13.3.9.2. Popular Recipient Organizations: Analysis by Number of Grants
13.3.9.3. Popular Recipient Organizations: Analysis by Grant Amount
13.3.10. Analysis by Region of Recipient Organization
14. KEY COMMMERCIALIZATION STRATEGIES
14.1. Chapter Overview
14.2. Successful Drug Launch Strategy: ROOTS Framework
14.3. Successful Drug Launch Strategy: Product Differentiation
14.4. Common Commercialization Strategies Adopted Across Different Stages of Product Development
14.5. Key Commercialization Strategies Adopted by the Companies Focused on Antibody Drug Conjugates
14.5.1. Participation in the Global Events
14.5.2. Collaboration with External Stakeholders and Pharmaceuticals Firms
14.5.3. Geographical Expansion
14.5.4. Awareness Through Product Website
14.6. Concluding Remarks
15. PROMOTIONAL ANALYSIS
15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Summary of Product Website
15.4. Summary of Patient Support Services and Informative Downloads
15.5. Adcetris: Promotional Analysis
15.5.1. Drug Overview
15.5.2. Product Website Analysis
15.5.2.1. Message for Healthcare Professional
15.5.2.2. Message for Patients
15.5.2.3. Informative Downloads
15.5.2.4. Patient Support Services
15.6. Besponsa: Promotional Analysis
15.6.1. Drug Overview
15.6.2. Product Website Analysis
15.6.2.1. Message for Healthcare Professional
15.6.2.2. Message for Patients
15.6.2.3. Informative Downloads
15.6.2.4. Patient Support Services
15.7. Enhertu: Promotional Analysis
15.7.1. Drug Overview
15.7.2. Product Website Analysis
15.7.2.1. Message for Healthcare Professional
15.7.2.2. Message for Patients
15.7.2.3. Informative Downloads
15.7.2.4. Patient Support Services
15.8. Kadcyla: Promotional Analysis
15.8.1. Drug Overview
15.8.2. Product Website Analysis
15.8.2.1. Message for Healthcare Professional
15.8.2.2. Message for patients
15.8.2.3. Informative Downloads
15.8.2.4. Patient Support Services
15.9. Mylotarg: Promotional Analysis
15.9.1. Drug Overview
15.9.2. Product Website Analysis
15.9.2.1. Message for Healthcare Professional
15.9.2.2. Message for patients
15.9.2.3. Informative Downloads
15.9.2.4. Patient Support Services
15.10. Polivy: Promotional Analysis
15.10.1. Drug Overview
15.10.2. Product Website Analysis
15.10.2.1. Message for Healthcare Professional
15.10.2.2. Message for Patients
15.10.2.3. Informative Downloads
15.10.2.4. Patient Support Services
15.11. Trodelvy: Promotional Analysis
15.11.1. Drug Overview
15.11.2. Product Website Analysis
15.11.2.1. Message for Healthcare Professional
15.11.2.2. Message for Patients
15.11.2.3. Informative Downloads
15.11.2.4. Patient Support Services
16. SUCCESS PROTOCOL ANALYSIS
16.1. Chapter Overview
16.2. Antibody Drug Conjugates: Success Protocol Analysis
16.3. Adcetris (Seagen / Takeda Oncology)
16.3.1. Overview
16.3.2. Approval Timeline
16.3.3. Success Protocol Analysis
16.4. Aidixi (RemeGen)
16.4.1. Overview
16.4.2. Approval Timeline
16.4.3. Success Protocol Analysis
16.5. Akalux (Rakuten Medical)
16.5.1. Overview
16.5.2. Approval Timeline
16.5.3. Success Protocol Analysis
16.6. Besponsa (Pfizer / UCB)
16.6.1. Overview
16.6.2. Approval Timeline
16.6.3. Success Protocol Analysis
16.7. Blenrep (GlaxoSmithKline)
16.7.1. Overview
16.7.2. Approval Timeline
16.7.3. Success Protocol Analysis
16.8. Elahere (ImmunoGen)
16.8.1. Overview
16.8.2. Approval Timeline
16.8.3. Success Protocol Analysis
16.9. Enhertu (Daiichi Sankyo / AstraZeneca)
16.9.1. Overview
16.9.2. Approval Timeline
16.9.3. Success Protocol Analysis
16.10. Kadcyla (Genentech / ImmunoGen)
16.10.1. Overview
16.10.2. Approval Timeline
16.10.3. Success Protocol Analysis
16.11. Padcev (Seagen / Astellas Pharma)
16.11.1. Overview
16.11.2. Approval Timeline
16.11.3. Success Protocol Analysis
16.12. Polivy (Genentech)
16.12.1. Overview
16.12.2. Approval Timeline
16.12.3. Success Protocol Analysis
16.13. Tivdak (Seagen / Genmab)
16.13.1. Overview
16.13.2. Approval Timeline
16.13.3. Success Protocol Analysis
16.14. Trodelvy (Gilead Sciences)
16.14.1. Overview
16.14.2. Approval Timeline
16.14.3. Success Protocol Analysis
16.15. Zynlonta (ADC Therapeutics)
16.15.1. Overview
16.15.2. Approval Timeline
16.15.3. Success Protocol Analysis
16.16. Concluding Remarks
17. NOVEL CONJUGATION AND LINKER TECHNOLOGY PLATFORMS
17.1. Chapter Overview
17.2. Antibody Drug Conjugates: Conjugation Technologies
17.2.1. Chemical Conjugation
17.2.2. Enzymatic Conjugation
17.3. Antibody Drug Conjugates: List of Conjugation Technologies
17.4. Antibody Drug Conjugates: Linker Technologies
17.4.1. Non-cleavable Linkers
17.4.2. Cleavable Linker
17.5. Antibody Drug Conjugates: List of Linker and Linker-Payload Technologies
17.6. Concluding Remarks
18. ASSESSMENT OF NON-CLINICAL DATA FIRST IN HUMAN DOSING
18.1. Chapter Overview
18.2. Antibody Drug Conjugates: Non-Clinical Studies
18.3. ICH S9 Guidelines
18.4. Investigational New Drug (IND)-Enabling Study Designs
18.4.1. Example Case: Kadcyla
18.5. Toxicities in Animal Models
18.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
18.7. Other Key Considerations for Study Design
19. COST PRICE ANALYSIS
19.1. Chapter Overview
19.2. Factors Contributing Towards the High Price of Antibody-Drug Conjugates
19.3. Antibody Drug Conjugates Market: Cost Price Analysis
19.3.1. On the Basis of Associated Costs
19.3.2. On the Basis of Competition
19.3.3. On the Basis of Patient Segment
19.4. Reimbursement Considerations for Antibody-Drug Conjugates
20. CASE STUDY 1: CONTRACT MANUFACTURING OF ANTIBODY-DRUG CONJUGATES
20.1. Chapter Overview
20.2. Key Steps in Antibody Drug Conjugate Manufacturing Process
20.3. Technical Challenges Related to Antibody Drug Conjugate Manufacturing
20.4. Challenges Associated with Supply Chain and Method Transfer
20.5. Limitations of In-House Manufacturing
20.6. Investments in Antibody Drug Conjugate Manufacturing Capability Expansions
20.7. Collaborations Established for Antibody-Drug Conjugate Manufacturing
20.8. Growing Demand for Antibody-Drug Conjugate Contract Manufacturing
20.9. CMOs with Linker Manufacturing Capabilities
20.10. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
20.11. CMOs with Conjugation Capabilities
20.12. Antibody Drug Conjugate One-Stop-Shops
20.13. Increasing Demand for One-Stop-Shops
21. CASE STUDY 2: COMPANION DIAGNOSTICS FOR ANTIBODY DRUG CONJUGATES THERAPEUTICS
21.1. Chapter Overview
21.1.1. Advantages of Companion Diagnostics
21.1.2. Challenges Associated with the Development of Companion Diagnostics
21.2. Companion Diagnostics for Antibody Drug Conjugates
21.3. Companion Diagnostics For Antibody Therapeutics
21.3.1. Analysis by Target Antigen
21.3.2. Analysis by Type of Cancer
21.4. Most Prominent Players: Analysis by Number of Tests
22. SWOT ANALYSIS
22.1. Chapter Overview
22.2. Strengths
22.2.1. Improved Safety and Patient Adherence
22.2.2. Rise of Next-Generation Conjugation Technologies
22.2.3. Robust Pipeline with Multiple Late Stage Product Candidates
22.2.4. Growing Involvement of Academic Institutes
22.3. Weaknesses
22.3.1. Technical Complexities Associated with Product Development
22.3.2. Manufacturing, Logistics and Supply Chain Challenges
22.3.3. Batch to Batch Inconsistencies
22.4. Opportunities
22.4.1. Increasing Collaborations and VC Funding
22.4.2. Widening Therapeutics Reach
22.4.3. Life Cycle Management
22.4.4. Combination Therapies
22.4.5. Opportunities for CMOs
22.5. Threats
22.5.1. Failure of Clinical / Marketed Candidates
22.5.2. Increased Competition from Other Therapeutic Classes
23. MARKET FORECAST AND OPPORTUNITY ANALYSIS
23.1. Chapter Overview
23.2. Forecast Methodology and Key Assumptions
23.3. Global Antibody Drug Conjugates Market, 2023-2035
23.3.1. Global Antibody Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035
23.3.1.1. Antibody Drug Conjugates Market for Breast Cancer, 2023-2035
23.3.1.2. Antibody Drug Conjugates Market for B-cell Lymphoma, 2023-2035
23.3.1.3. Antibody Drug Conjugates Market for Lung Cancer, 2023-2035
23.3.1.4. Antibody Drug Conjugates Market for Multiple Myeloma, 2023-2035
23.3.1.5. Antibody Drug Conjugates Market for Renal Cancer, 2023-2035
23.3.1.6. Antibody Drug Conjugates Market for Gastric Cancer, 2023-2035
23.3.1.7. Antibody Drug Conjugates Market for Cervical Cancer, 2023-2035
23.3.1.8. Antibody Drug Conjugates Market for Acute Lymphoblastic Leukemia, 2023-2035
23.3.1.9. Antibody Drug Conjugates Market for Other Disease Indications, 2023-2035
23.3.2. Antibody Drug Conjugates Market: Distribution by Therapeutic Area, 2023 and 2035
23.3.2.1. Antibody Drug Conjugates Market for Solid Tumors, 2023-2035
23.3.2.2. Antibody Drug Conjugates Market for Hematological Cancer, 2023-2035
23.3.3. Global Antibody Drug Conjugates Market: Distribution by Linker, 2023 and 2035
23.3.3.1. Antibody Drug Conjugates Market for Valine-Citrulline Linker, 2023-2035
23.3.3.2. Antibody Drug Conjugates Market for Tetrapeptide-Based Linker, 2023-2035
23.3.3.3. Antibody Drug Conjugates Market for Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate Linker, 2023-2035
23.3.3.4. Antibody Drug Conjugates Market for Maleimide Linker, 2023-2035
23.3.3.5. Antibody Drug Conjugates Market for Maleimidocaproyl Linker, 2023-2035
23.3.3.6. Antibody Drug Conjugates Market for Valine-Alanine Linker, 2023-2035
23.3.3.7. Antibody Drug Conjugates Market for Hydrazone (4-(4-acetylphenoxy) butanoic acid (AcBut) Linker, 2023-2035
23.3.3.8. Antibody Drug Conjugates Market for Other Linkers, 2023-2035
23.3.4. Antibody Drug Conjugates Market: Distribution by Type of Payload, 2023 and 2035
23.3.4.1. Antibody Drug Conjugates Market for Monomethyl Auristatin E Payloads, 2023-2035
23.3.4.2. Antibody Drug Conjugates Market for DM1 Payloads, 2023-2035
23.3.4.3. Antibody Drug Conjugates Market for SN-38 / Irinotecan Payloads, 2023-2035
23.3.4.4. Antibody Drug Conjugates Market for Monomethyl Auristatin F Payloads, 2023-2035
23.3.4.5. Antibody Drug Conjugates Market for Duocarmycin Payloads, 2023-2035
23.3.4.6. Antibody Drug Conjugates Market for SG3199 Payloads, 2023-2035
23.3.4.7. Antibody Drug Conjugates Market for Ozogamicin Payloads, 2023-2035
23.3.4.8. Antibody Drug Conjugates Market for DM4 Payloads, 2023-2035
23.3.4.9. Antibody Drug Conjugates Market for Other Payloads, 2023-2035
23.3.5. Global Antibody Drug Conjugates Market: Distribution by Target Antigen, 2023 and 2035
23.3.5.1. Antibody Drug Conjugates Market for HER-2 (ERBB2), 2023-2035
23.3.5.2. Antibody Drug Conjugates Market for CD79b, 2023-2035
23.3.5.3. Antibody Drug Conjugates Market for TROP-2, 2023-2035
23.3.5.4. Antibody Drug Conjugates Market for BCMA (TNFRSF17 / BCM), 2023-2035
23.3.5.5. Antibody Drug Conjugates Market for CD19, 2023-2035
23.3.5.6. Antibody Drug Conjugates Market for Nectin 4, 2023-2035
23.3.5.7. Antibody Drug Conjugates Market for Tissue Factor, 2023-2035
23.3.5.8. Antibody Drug Conjugates Market for CD22, 2023-2035
23.3.5.9. Antibody Drug Conjugates Market for CD30, 2023-2035
23.3.5.10. Antibody Drug Conjugates Market for CEACAM5, 2023-2035
23.3.5.11. Antibody Drug Conjugates Market for Other Target Antigens, 2023-2035
23.3.6. Antibody Drug Conjugates Market: Distribution by Geographical Regions, 2023 and 2035
23.3.6.1. Antibody Drug Conjugates Market in North America, 2023-2035
23.3.6.1.1. Antibody Drug Conjugates Market in US, 2023-2035
23.3.6.1.2. Antibody Drug Conjugates Market in Canada, 2023-2035
23.3.6.2. Antibody Drug Conjugates Market in Europe, 2023-2035
23.3.6.2.1. Antibody Drug Conjugates Market in Germany, 2023-2035
23.3.6.2.2. Antibody Drug Conjugates Market in UK, 2023-2035
23.3.6.2.3. Antibody Drug Conjugates Market in France, 2023-2035
23.3.6.2.4. Antibody Drug Conjugates Market in Italy, 2023-2035
23.3.6.2.5. Antibody Drug Conjugates Market in Spain, 2023-2035
23.3.6.3. Antibody Drug Conjugates Market in Asia-Pacific, 2023-2035
23.3.6.3.1. Antibody Drug Conjugates Market in China, 2023-2035
23.3.6.3.2. Antibody Drug Conjugates Market in Australia, 2023-2035
23.3.6.3.3. Antibody Drug Conjugates Market in Japan, 2023-2035
23.4. Antibody Drug Conjugates Market: Product-wise Sales Forecast, 2023-2035
23.4.1. Adcetris
23.4.1.1. Sales Forecast (USD Billion)
23.4.1.2. Net Present Value (USD Billion)
23.4.1.3. Value Creation Analysis
23.4.2. Aidixi
23.4.2.1. Sales Forecast (USD Billion)
23.4.2.2. Net Present Value (USD Billion)
23.4.2.3. Value Creation Analysis
23.4.3. Besponsa
23.4.3.1. Sales Forecast (USD Billion)
23.4.3.2. Net Present Value (USD Billion)
23.4.3.3. Value Creation Analysis
23.4.4. Blenrep
23.4.4.1. Sales Forecast (USD Billion)
23.4.4.2. Net Present Value (USD Billion)
23.4.4.3. Value Creation Analysis
23.4.5. Elahere
23.4.5.1. Sales Forecast (USD Billion)
23.4.5.2. Net Present Value (USD Billion)
23.4.5.3. Value Creation Analysis
23.4.6. Enhertu
23.4.6.1. Sales Forecast (USD Billion)
23.4.6.2. Net Present Value (USD Billion)
23.4.6.3. Value Creation Analysis
23.4.7. Kadcyla
23.4.7.1. Sales Forecast (USD Billion)
23.4.7.2. Net Present Value (USD Billion)
23.4.7.3. Value Creation Analysis
23.4.8. Padcev
23.4.8.1. Sales Forecast (USD Billion)
23.4.8.2. Net Present Value (USD Billion)
23.4.8.3. Value Creation Analysis
23.4.9. Polivy
23.4.9.1. Sales Forecast (USD Billion)
23.4.9.2. Net Present Value (USD Billion)
23.4.9.3. Value Creation Analysis
23.4.10. Tivdak
23.4.10.1. Sales Forecast (USD Billion)
23.4.10.2. Net Present Value (USD Billion)
23.4.10.3. Value Creation Analysis
23.4.11. Trodelvy
23.4.11.1. Sales Forecast (USD Billion)
23.4.11.2. Net Present Value (USD Billion)
23.4.11.3. Value Creation Analysis
23.4.12. Zynlonta
23.4.12.1. Sales Forecast (USD Billion)
23.4.12.2. Net Present Value (USD Billion)
23.4.12.3. Value Creation Analysis
23.4.13. Datopotamab Deruxtecan
23.4.13.1. Sales Forecast (USD Billion)
23.4.13.2. Net Present Value (USD Billion)
23.4.13.3. Value Creation Analysis
23.4.14. Patritumab Deruxtecan
23.4.14.1. Sales Forecast (USD Billion)
23.4.14.2. Net Present Value (USD Billion)
23.4.14.3. Value Creation Analysis
23.4.15. SHR-A1811
23.4.15.1. Sales Forecast (USD Billion)
23.4.15.2. Net Present Value (USD Billion)
23.4.15.3. Value Creation Analysis
23.4.16. SKB264
23.4.16.1. Sales Forecast (USD Billion)
23.4.16.2. Net Present Value (USD Billion)
23.4.16.3. Value Creation Analysis
23.4.17. TAA013
23.4.17.1. Sales Forecast (USD Billion)
23.4.17.2. Net Present Value (USD Billion)
23.4.17.3. Value Creation Analysis
23.4.18. Telisotuzumab Vedotin
23.4.18.1. Sales Forecast (USD Billion)
23.4.18.2. Net Present Value (USD Billion)
23.4.18.3. Value Creation Analysis
23.4.19. Trastuzumab Duocarmazine
23.4.19.1. Sales Forecast (USD Billion)
23.4.19.2. Net Present Value (USD Billion)
23.4.19.3. Value Creation Analysis
23.4.20. Tusamitamab Ravtansine
23.4.20.1. Sales Forecast (USD Billion)
23.4.20.2. Net Present Value (USD Billion)
23.4.20.3. Value Creation Analysis
23.4.21. Upifitamab Rilsodotin
23.4.21.1. Sales Forecast (USD Billion)
23.4.21.2. Net Present Value (USD Billion)
23.4.21.3. Value Creation Analysis
24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Oxford Biotherapeutics
24.2.1. Company Snapshot
24.2.2. Interview Transcript: Christian Rohlff, Founder and Chief Executive Officer
24.3. Angiex
24.3.1. Company Snapshot
24.3.2. Interview Transcript: Paul Jaminet, Founder and Chief Operating Officer
24.4. Syndivia
24.4.1. Company Snapshot
24.4.2. Interview Transcript: Sasha Koniev, Co-Founder and Chief Executive Officer
24.5. BSP Pharmaceuticals
24.5.1. Company Snapshot
24.5.2. Interview Transcript: Aldo Braca, President and Chief Executive Officer and Giorgio Salciarini, Technical Business Development Senior Manager
24.6. PolyTherics (an Abzena company)
24.6.1. Company Snapshot
24.6.2. Interview Transcript: John Burt, Former Chief Executive Officer
24.7. CureMeta
24.7.1. Company Snapshot
24.7.2. Interview Transcript: Michael Schopperle, Founder and Chief Executive Officer
24.8. CytomX Therapeutics
24.8.1. Company Snapshot
24.8.2. Interview Transcript: Jeff Landau, Chief Business Officer and Head of Strategy
24.9. NBE-Therapeutics
24.9.1. Company Snapshot
24.9.2. Interview Transcript: Wouter Verhoeven, Former Chief Business Officer
24.10. Cerbios-Pharma
24.10.1. Company Snapshot
24.10.2. Interview Transcript: Denis Angioletti, Chief Commercial Officer
24.11. Eisai
24.11.1. Company Snapshot
24.11.2. Interview Transcript: Toshimitsu Uenaka, President and Takashi Owa, Senior Vice President and Chief Scientific Officer
24.12. AbTis
24.12.1. Company Snapshot
24.12.2. Interview Transcript: Justin Oh, Chief Business Officer
24.13. AmbrX
24.13.1. Company Snapshot
24.13.2. Interview Transcript: Sukumar Sakamuri, Former Vice President and Head of Chemistry
24.14. Synaffix
24.14.1. Company Snapshot
24.14.2. Interview Transcript: Anthony DeBoer, Vice President, Business Development
24.15. Pierre Fabre
24.15.1. Company Snapshot
24.15.2. Interview Transcript: Christian Bailly, Former Director
24.16. Catalent Pharma Solutions
24.16.1. Company Snapshot
24.16.2. Interview Transcript: Jennifer L. Mitcham, Former Director, SMARTag ADCs and Bioconjugates and Stacy McDonald, Former Group Product Manager
24.17. Lonza
24.17.1. Company Snapshot
24.17.2. Interview Transcript: Laurent Ducry, Former Head of Bioconjugates Commercial Development
24.18. Piramal Healthcare
24.18.1. Company Snapshot
24.18.2. Interview Transcript: Mark Wright, Former Site Head
24.19. Ajinomoto Bio-Pharma Services
24.19.1. Company Snapshot
24.19.2. Interview Transcript: Tatsuya Okuzumi, General Manager, Business Development, CDMO Business
24.20. Cardiff University
24.20.1. Company Snapshot
24.20.2. Interview Transcript: Alan Burnett, Professor, School of Medicine
24.21. Anonymous, Director, Business Development, Leading CMO
24.22. Anonymous, Chief Executive Officer, Leading CMO
25. CONCLUSION
26. APPENDIX 1: TABULATED DATA
27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Antibody Drug Conjugate Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Antibody Drug Conjugates
3.3.1. History of Antibody Drug Conjugates
3.3.2. Difference between Small Molecule Drugs, Monoclonal Antibody Therapies and Antibody Drug Conjugates
3.3.3. Components of Antibody Drug Conjugates
3.3.3.1. Antibody
3.3.3.2. Cytotoxin
3.3.3.3. Linker
3.3.4. Advantages of Antibody Drug Conjugates Therapeutics over Traditional Therapeutics
3.3.5. Pharmacokinetic Properties of Antibody-Drug Conjugates
3.3.5.1. Absorption
3.3.5.2. Distribution
3.3.5.3. Metabolism and Elimination
3.4. Concluding Remarks
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Antibody Drug Conjugates: Therapies Pipeline
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Target Disease Indication
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Line of Treatment
4.2.5. Analysis by Dosing Frequency
4.2.6. Analysis by Type of Therapy
4.2.7. Analysis by Target Antigen
4.2.8. Analysis by Antibody Isotype
4.2.9. Analysis by Payload / Cytotoxin / Warhead
4.2.10. Analysis by Type of Payload
4.2.11. Analysis by Linker
4.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)
4.3. Antibody Drug Conjugate: List of Therapy Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company size and Location of Headquarters
4.3.5. Most Active Players: Analysis by Number of Therapies
5. TARGET COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Parameters
5.3. Methodology
5.4. Target Competitiveness Analysis: Key Targets of Antibody Drug Conjugates
5.4.1. Three-Dimensional Bubble Analysis
5.4.1.1. Targets of Approved / Marketed Drugs
5.4.1.2. Targets of Phase III Drugs
5.4.1.3. Targets of Phase II Drugs
5.4.1.4. Targets of Phase I Drugs
5.4.1.5. Targets of Pre-Clinical Drugs
5.4.2. Six-Dimensional Spider Web Analysis
6. COMPANY AND DRUG PROFILES
6.1. Chapter Overview
6.2. ADC Therapeutics
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Pipeline Overview
6.2.3.1. Zynlonta
6.2.4. Recent Developments and Future Outlook
6.3. Astellas Pharma
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Pipeline Overview
6.3.3.1. Padcev
6.3.4. Recent Developments and Future Outlook
6.4. AstraZeneca
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Pipeline Overview
6.4.3.1. Enhertu
6.4.4. Recent Developments and Future Outlook
6.5. Byondis
6.5.1. Company Overview
6.5.2. Financial Information
6.5.2.1. Pipeline Overview
6.5.3. Trastuzumab duocarmazine
6.5.4. Recent Developments and Future Outlook
6.6. Daiichi Sankyo
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Pipeline Overview
6.6.3.1. Enhertu
6.6.4. Recent Developments and Future Outlook
6.7. Genentech (Subsidiary of Roche)
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Pipeline Overview
6.7.3.1. Kadcyla
6.7.3.2. Polivy
6.7.4. Recent Developments and Future Outlook
6.8. Gilead Sciences
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Pipeline Overview
6.8.3.1. Trodelvy
6.8.4. Recent Developments and Future Outlook
6.9. ImmunoGen
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Pipeline Overview
6.9.3.1. Elahere
6.9.4. Recent Developments and Future Outlook
6.10. Pfizer
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Pipeline Overview
6.10.3.1. Mylotarg
6.10.3.2. Besponsa
6.10.4. Recent Developments and Future Outlook
6.11. RemeGen
6.11.1. Company Overview
6.11.2. Financial Information
6.11.3. Pipeline Overview
6.11.3.1. Disitamab vedotin
6.11.4. Recent Developments and Future Outlook
6.12. Seagen
6.12.1. Company Overview
6.12.2. Financial Information
6.12.3. Pipeline Overview
6.12.3.1. Adcetris
6.12.3.2. Padcev
6.12.3.3. Tivdak
6.12.4. Recent Developments and Future Outlook
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Antibody Drug Conjugates: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Status
7.3.3. Analysis by Trial Status and Patients Enrolled
7.3.4. Analysis by Trial Registration Year and Trial Status
7.3.5. Analysis by Trial Registration Year and Patients Enrolled
7.3.6. Analysis by Trial Phase
7.3.7. Analysis by Trial Phase and Patients Enrolled
7.3.8. Analysis by Type of Sponsor / Collaborator
7.3.9. Analysis by Target Population
7.3.10. Analysis by Study Design
7.3.11. Most Active Industry Players: Analysis by Number of Trials
7.3.12. Most Active Non-Industry Players: Analysis by Number of Trials
7.3.13. Analysis of Clinical Trials by Geography
7.3.14. Analysis of Patients Enrolled by Geography
8. KEY OPINION LEADERS
8.1. Chapter Overview
8.2. Assumption and Key Parameters
8.3. Methodology
8.4. Antibody Drug Conjugates: Key Opinion Leaders
8.4.1. Analysis by Type of KOLs
8.4.2. Analysis by Qualification
8.4.3. Analysis by Affiliated Organization
8.4.4. Analysis by Type of Organization
8.4.5. Analysis by Geographical Location of KOLs
8.4.6. Most Prominent KOLs: Analysis by KOLs Activeness, Expertise and Strength
8.4.7. Most Prominent KOLs: Analysis by RA score
8.4.8. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
9. COMBINATION THERAPIES
9.1. Chapter Overview
9.2. Combination Therapies: History of Development
9.3. Combination Therapies: FDA Guidelines
9.3.1. Combination of Marketed Drugs
9.3.2. Combinations of Marketed Drugs with New Molecular Entities
9.3.3. Combination of New Molecular Entities
9.4. Combination Therapies: Antibody Drug Conjugates
9.4.1. Completed / Ongoing Clinical Studies of Antibody Drug Conjugates
9.4.1.1. Analysis by Type of Therapy
9.4.2. Completed / Ongoing Clinical Studies of Antibody Drug Conjugate-based Combination Therapies
9.4.2.1. Analysis by Phase of Development
9.4.2.2. Analysis by Trial Status
9.4.2.3. Analysis by Target Disease Indication
9.4.2.4. Most Popular Antibody Drug Conjugates Used in Combination Therapies: Analysis by Number of Trials
9.4.2.5. Most Popular Drug Class Used in Combination Therapies: Analysis by Number of Trials
9.4.2.6. Analysis by Target Disease Indication and Drug Class Used in Antibody Drug Conjugate-based Combination Therapies
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Antibody Drug Conjugates: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Purpose of Partnership
10.3.5. Analysis by Type of Partner
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.3.7. Analysis by Geography
10.3.7.1. International and Local Agreements
10.3.7.2. Intercontinental and Intracontinental Agreements
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Antibody Drug Conjugates: List of Funding and Investment Analysis
11.3.1. Analysis by Year of Funding
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Year and Type of Funding
11.3.5. Analysis by Type of Investor
11.3.6. Analysis by Amount Invested by Geography
11.3.6.1. Analysis by Region
11.3.6.2. Analysis by Country
11.3.7. Most Active Players: Analysis by Number of Funding Instances
11.3.8. Most Active Players: Analysis by Amount Invested
11.3.9. Key Investors: Analysis by Number of Funding Instances
12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Antibody Drug Conjugates: Patent Analysis
12.3.1. Analysis by Patent Publication Year
12.3.2. Analysis by Patent Application Year
12.3.3. Analysis by Annual Number of Granted Patents and Patent Applications
12.3.4. Analysis by Patent Jurisdiction
12.3.5. Analysis by CPC Symbols
12.3.6. Analysis by Type of Applicant
12.3.7. Leading Industry Players: Analysis by Number of Patents
12.3.8. Leading Non-Industry Players: Analysis by Number of Patents
12.3.9. Leading Individual Assignees: Analysis by Number of Patents
12.4. Antibody Drug Conjugate: Patent Benchmarking Analysis
12.4.1. Analysis by Patent Characteristics
12.5. Antibody Drug Conjugate: Patent Valuation
12.6. Leading Patents by Number of Citations
13. ACADEMIC GRANTS ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Antibody Drug Conjugates: Grants Analysis
13.3.1. Analysis by Year of Grant Award
13.3.2. Analysis by Amount Awarded
13.3.3. Analysis by Funding Institute
13.3.4. Analysis by Support Period
13.3.5. Analysis by Type of Grant Application
13.3.6. Analysis by Purpose of Grant Award
13.3.7. Analysis by Activity Code
13.3.8. Analysis by Study Section Involved
13.3.9. Popular NIH Departments: Analysis by Number of Grants
13.3.9.1. Prominent Program Officers: Analysis by Number of Grants
13.3.9.2. Popular Recipient Organizations: Analysis by Number of Grants
13.3.9.3. Popular Recipient Organizations: Analysis by Grant Amount
13.3.10. Analysis by Region of Recipient Organization
14. KEY COMMMERCIALIZATION STRATEGIES
14.1. Chapter Overview
14.2. Successful Drug Launch Strategy: ROOTS Framework
14.3. Successful Drug Launch Strategy: Product Differentiation
14.4. Common Commercialization Strategies Adopted Across Different Stages of Product Development
14.5. Key Commercialization Strategies Adopted by the Companies Focused on Antibody Drug Conjugates
14.5.1. Participation in the Global Events
14.5.2. Collaboration with External Stakeholders and Pharmaceuticals Firms
14.5.3. Geographical Expansion
14.5.4. Awareness Through Product Website
14.6. Concluding Remarks
15. PROMOTIONAL ANALYSIS
15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Summary of Product Website
15.4. Summary of Patient Support Services and Informative Downloads
15.5. Adcetris: Promotional Analysis
15.5.1. Drug Overview
15.5.2. Product Website Analysis
15.5.2.1. Message for Healthcare Professional
15.5.2.2. Message for Patients
15.5.2.3. Informative Downloads
15.5.2.4. Patient Support Services
15.6. Besponsa: Promotional Analysis
15.6.1. Drug Overview
15.6.2. Product Website Analysis
15.6.2.1. Message for Healthcare Professional
15.6.2.2. Message for Patients
15.6.2.3. Informative Downloads
15.6.2.4. Patient Support Services
15.7. Enhertu: Promotional Analysis
15.7.1. Drug Overview
15.7.2. Product Website Analysis
15.7.2.1. Message for Healthcare Professional
15.7.2.2. Message for Patients
15.7.2.3. Informative Downloads
15.7.2.4. Patient Support Services
15.8. Kadcyla: Promotional Analysis
15.8.1. Drug Overview
15.8.2. Product Website Analysis
15.8.2.1. Message for Healthcare Professional
15.8.2.2. Message for patients
15.8.2.3. Informative Downloads
15.8.2.4. Patient Support Services
15.9. Mylotarg: Promotional Analysis
15.9.1. Drug Overview
15.9.2. Product Website Analysis
15.9.2.1. Message for Healthcare Professional
15.9.2.2. Message for patients
15.9.2.3. Informative Downloads
15.9.2.4. Patient Support Services
15.10. Polivy: Promotional Analysis
15.10.1. Drug Overview
15.10.2. Product Website Analysis
15.10.2.1. Message for Healthcare Professional
15.10.2.2. Message for Patients
15.10.2.3. Informative Downloads
15.10.2.4. Patient Support Services
15.11. Trodelvy: Promotional Analysis
15.11.1. Drug Overview
15.11.2. Product Website Analysis
15.11.2.1. Message for Healthcare Professional
15.11.2.2. Message for Patients
15.11.2.3. Informative Downloads
15.11.2.4. Patient Support Services
16. SUCCESS PROTOCOL ANALYSIS
16.1. Chapter Overview
16.2. Antibody Drug Conjugates: Success Protocol Analysis
16.3. Adcetris (Seagen / Takeda Oncology)
16.3.1. Overview
16.3.2. Approval Timeline
16.3.3. Success Protocol Analysis
16.4. Aidixi (RemeGen)
16.4.1. Overview
16.4.2. Approval Timeline
16.4.3. Success Protocol Analysis
16.5. Akalux (Rakuten Medical)
16.5.1. Overview
16.5.2. Approval Timeline
16.5.3. Success Protocol Analysis
16.6. Besponsa (Pfizer / UCB)
16.6.1. Overview
16.6.2. Approval Timeline
16.6.3. Success Protocol Analysis
16.7. Blenrep (GlaxoSmithKline)
16.7.1. Overview
16.7.2. Approval Timeline
16.7.3. Success Protocol Analysis
16.8. Elahere (ImmunoGen)
16.8.1. Overview
16.8.2. Approval Timeline
16.8.3. Success Protocol Analysis
16.9. Enhertu (Daiichi Sankyo / AstraZeneca)
16.9.1. Overview
16.9.2. Approval Timeline
16.9.3. Success Protocol Analysis
16.10. Kadcyla (Genentech / ImmunoGen)
16.10.1. Overview
16.10.2. Approval Timeline
16.10.3. Success Protocol Analysis
16.11. Padcev (Seagen / Astellas Pharma)
16.11.1. Overview
16.11.2. Approval Timeline
16.11.3. Success Protocol Analysis
16.12. Polivy (Genentech)
16.12.1. Overview
16.12.2. Approval Timeline
16.12.3. Success Protocol Analysis
16.13. Tivdak (Seagen / Genmab)
16.13.1. Overview
16.13.2. Approval Timeline
16.13.3. Success Protocol Analysis
16.14. Trodelvy (Gilead Sciences)
16.14.1. Overview
16.14.2. Approval Timeline
16.14.3. Success Protocol Analysis
16.15. Zynlonta (ADC Therapeutics)
16.15.1. Overview
16.15.2. Approval Timeline
16.15.3. Success Protocol Analysis
16.16. Concluding Remarks
17. NOVEL CONJUGATION AND LINKER TECHNOLOGY PLATFORMS
17.1. Chapter Overview
17.2. Antibody Drug Conjugates: Conjugation Technologies
17.2.1. Chemical Conjugation
17.2.2. Enzymatic Conjugation
17.3. Antibody Drug Conjugates: List of Conjugation Technologies
17.4. Antibody Drug Conjugates: Linker Technologies
17.4.1. Non-cleavable Linkers
17.4.2. Cleavable Linker
17.5. Antibody Drug Conjugates: List of Linker and Linker-Payload Technologies
17.6. Concluding Remarks
18. ASSESSMENT OF NON-CLINICAL DATA FIRST IN HUMAN DOSING
18.1. Chapter Overview
18.2. Antibody Drug Conjugates: Non-Clinical Studies
18.3. ICH S9 Guidelines
18.4. Investigational New Drug (IND)-Enabling Study Designs
18.4.1. Example Case: Kadcyla
18.5. Toxicities in Animal Models
18.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
18.7. Other Key Considerations for Study Design
19. COST PRICE ANALYSIS
19.1. Chapter Overview
19.2. Factors Contributing Towards the High Price of Antibody-Drug Conjugates
19.3. Antibody Drug Conjugates Market: Cost Price Analysis
19.3.1. On the Basis of Associated Costs
19.3.2. On the Basis of Competition
19.3.3. On the Basis of Patient Segment
19.4. Reimbursement Considerations for Antibody-Drug Conjugates
20. CASE STUDY 1: CONTRACT MANUFACTURING OF ANTIBODY-DRUG CONJUGATES
20.1. Chapter Overview
20.2. Key Steps in Antibody Drug Conjugate Manufacturing Process
20.3. Technical Challenges Related to Antibody Drug Conjugate Manufacturing
20.4. Challenges Associated with Supply Chain and Method Transfer
20.5. Limitations of In-House Manufacturing
20.6. Investments in Antibody Drug Conjugate Manufacturing Capability Expansions
20.7. Collaborations Established for Antibody-Drug Conjugate Manufacturing
20.8. Growing Demand for Antibody-Drug Conjugate Contract Manufacturing
20.9. CMOs with Linker Manufacturing Capabilities
20.10. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
20.11. CMOs with Conjugation Capabilities
20.12. Antibody Drug Conjugate One-Stop-Shops
20.13. Increasing Demand for One-Stop-Shops
21. CASE STUDY 2: COMPANION DIAGNOSTICS FOR ANTIBODY DRUG CONJUGATES THERAPEUTICS
21.1. Chapter Overview
21.1.1. Advantages of Companion Diagnostics
21.1.2. Challenges Associated with the Development of Companion Diagnostics
21.2. Companion Diagnostics for Antibody Drug Conjugates
21.3. Companion Diagnostics For Antibody Therapeutics
21.3.1. Analysis by Target Antigen
21.3.2. Analysis by Type of Cancer
21.4. Most Prominent Players: Analysis by Number of Tests
22. SWOT ANALYSIS
22.1. Chapter Overview
22.2. Strengths
22.2.1. Improved Safety and Patient Adherence
22.2.2. Rise of Next-Generation Conjugation Technologies
22.2.3. Robust Pipeline with Multiple Late Stage Product Candidates
22.2.4. Growing Involvement of Academic Institutes
22.3. Weaknesses
22.3.1. Technical Complexities Associated with Product Development
22.3.2. Manufacturing, Logistics and Supply Chain Challenges
22.3.3. Batch to Batch Inconsistencies
22.4. Opportunities
22.4.1. Increasing Collaborations and VC Funding
22.4.2. Widening Therapeutics Reach
22.4.3. Life Cycle Management
22.4.4. Combination Therapies
22.4.5. Opportunities for CMOs
22.5. Threats
22.5.1. Failure of Clinical / Marketed Candidates
22.5.2. Increased Competition from Other Therapeutic Classes
23. MARKET FORECAST AND OPPORTUNITY ANALYSIS
23.1. Chapter Overview
23.2. Forecast Methodology and Key Assumptions
23.3. Global Antibody Drug Conjugates Market, 2023-2035
23.3.1. Global Antibody Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035
23.3.1.1. Antibody Drug Conjugates Market for Breast Cancer, 2023-2035
23.3.1.2. Antibody Drug Conjugates Market for B-cell Lymphoma, 2023-2035
23.3.1.3. Antibody Drug Conjugates Market for Lung Cancer, 2023-2035
23.3.1.4. Antibody Drug Conjugates Market for Multiple Myeloma, 2023-2035
23.3.1.5. Antibody Drug Conjugates Market for Renal Cancer, 2023-2035
23.3.1.6. Antibody Drug Conjugates Market for Gastric Cancer, 2023-2035
23.3.1.7. Antibody Drug Conjugates Market for Cervical Cancer, 2023-2035
23.3.1.8. Antibody Drug Conjugates Market for Acute Lymphoblastic Leukemia, 2023-2035
23.3.1.9. Antibody Drug Conjugates Market for Other Disease Indications, 2023-2035
23.3.2. Antibody Drug Conjugates Market: Distribution by Therapeutic Area, 2023 and 2035
23.3.2.1. Antibody Drug Conjugates Market for Solid Tumors, 2023-2035
23.3.2.2. Antibody Drug Conjugates Market for Hematological Cancer, 2023-2035
23.3.3. Global Antibody Drug Conjugates Market: Distribution by Linker, 2023 and 2035
23.3.3.1. Antibody Drug Conjugates Market for Valine-Citrulline Linker, 2023-2035
23.3.3.2. Antibody Drug Conjugates Market for Tetrapeptide-Based Linker, 2023-2035
23.3.3.3. Antibody Drug Conjugates Market for Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate Linker, 2023-2035
23.3.3.4. Antibody Drug Conjugates Market for Maleimide Linker, 2023-2035
23.3.3.5. Antibody Drug Conjugates Market for Maleimidocaproyl Linker, 2023-2035
23.3.3.6. Antibody Drug Conjugates Market for Valine-Alanine Linker, 2023-2035
23.3.3.7. Antibody Drug Conjugates Market for Hydrazone (4-(4-acetylphenoxy) butanoic acid (AcBut) Linker, 2023-2035
23.3.3.8. Antibody Drug Conjugates Market for Other Linkers, 2023-2035
23.3.4. Antibody Drug Conjugates Market: Distribution by Type of Payload, 2023 and 2035
23.3.4.1. Antibody Drug Conjugates Market for Monomethyl Auristatin E Payloads, 2023-2035
23.3.4.2. Antibody Drug Conjugates Market for DM1 Payloads, 2023-2035
23.3.4.3. Antibody Drug Conjugates Market for SN-38 / Irinotecan Payloads, 2023-2035
23.3.4.4. Antibody Drug Conjugates Market for Monomethyl Auristatin F Payloads, 2023-2035
23.3.4.5. Antibody Drug Conjugates Market for Duocarmycin Payloads, 2023-2035
23.3.4.6. Antibody Drug Conjugates Market for SG3199 Payloads, 2023-2035
23.3.4.7. Antibody Drug Conjugates Market for Ozogamicin Payloads, 2023-2035
23.3.4.8. Antibody Drug Conjugates Market for DM4 Payloads, 2023-2035
23.3.4.9. Antibody Drug Conjugates Market for Other Payloads, 2023-2035
23.3.5. Global Antibody Drug Conjugates Market: Distribution by Target Antigen, 2023 and 2035
23.3.5.1. Antibody Drug Conjugates Market for HER-2 (ERBB2), 2023-2035
23.3.5.2. Antibody Drug Conjugates Market for CD79b, 2023-2035
23.3.5.3. Antibody Drug Conjugates Market for TROP-2, 2023-2035
23.3.5.4. Antibody Drug Conjugates Market for BCMA (TNFRSF17 / BCM), 2023-2035
23.3.5.5. Antibody Drug Conjugates Market for CD19, 2023-2035
23.3.5.6. Antibody Drug Conjugates Market for Nectin 4, 2023-2035
23.3.5.7. Antibody Drug Conjugates Market for Tissue Factor, 2023-2035
23.3.5.8. Antibody Drug Conjugates Market for CD22, 2023-2035
23.3.5.9. Antibody Drug Conjugates Market for CD30, 2023-2035
23.3.5.10. Antibody Drug Conjugates Market for CEACAM5, 2023-2035
23.3.5.11. Antibody Drug Conjugates Market for Other Target Antigens, 2023-2035
23.3.6. Antibody Drug Conjugates Market: Distribution by Geographical Regions, 2023 and 2035
23.3.6.1. Antibody Drug Conjugates Market in North America, 2023-2035
23.3.6.1.1. Antibody Drug Conjugates Market in US, 2023-2035
23.3.6.1.2. Antibody Drug Conjugates Market in Canada, 2023-2035
23.3.6.2. Antibody Drug Conjugates Market in Europe, 2023-2035
23.3.6.2.1. Antibody Drug Conjugates Market in Germany, 2023-2035
23.3.6.2.2. Antibody Drug Conjugates Market in UK, 2023-2035
23.3.6.2.3. Antibody Drug Conjugates Market in France, 2023-2035
23.3.6.2.4. Antibody Drug Conjugates Market in Italy, 2023-2035
23.3.6.2.5. Antibody Drug Conjugates Market in Spain, 2023-2035
23.3.6.3. Antibody Drug Conjugates Market in Asia-Pacific, 2023-2035
23.3.6.3.1. Antibody Drug Conjugates Market in China, 2023-2035
23.3.6.3.2. Antibody Drug Conjugates Market in Australia, 2023-2035
23.3.6.3.3. Antibody Drug Conjugates Market in Japan, 2023-2035
23.4. Antibody Drug Conjugates Market: Product-wise Sales Forecast, 2023-2035
23.4.1. Adcetris
23.4.1.1. Sales Forecast (USD Billion)
23.4.1.2. Net Present Value (USD Billion)
23.4.1.3. Value Creation Analysis
23.4.2. Aidixi
23.4.2.1. Sales Forecast (USD Billion)
23.4.2.2. Net Present Value (USD Billion)
23.4.2.3. Value Creation Analysis
23.4.3. Besponsa
23.4.3.1. Sales Forecast (USD Billion)
23.4.3.2. Net Present Value (USD Billion)
23.4.3.3. Value Creation Analysis
23.4.4. Blenrep
23.4.4.1. Sales Forecast (USD Billion)
23.4.4.2. Net Present Value (USD Billion)
23.4.4.3. Value Creation Analysis
23.4.5. Elahere
23.4.5.1. Sales Forecast (USD Billion)
23.4.5.2. Net Present Value (USD Billion)
23.4.5.3. Value Creation Analysis
23.4.6. Enhertu
23.4.6.1. Sales Forecast (USD Billion)
23.4.6.2. Net Present Value (USD Billion)
23.4.6.3. Value Creation Analysis
23.4.7. Kadcyla
23.4.7.1. Sales Forecast (USD Billion)
23.4.7.2. Net Present Value (USD Billion)
23.4.7.3. Value Creation Analysis
23.4.8. Padcev
23.4.8.1. Sales Forecast (USD Billion)
23.4.8.2. Net Present Value (USD Billion)
23.4.8.3. Value Creation Analysis
23.4.9. Polivy
23.4.9.1. Sales Forecast (USD Billion)
23.4.9.2. Net Present Value (USD Billion)
23.4.9.3. Value Creation Analysis
23.4.10. Tivdak
23.4.10.1. Sales Forecast (USD Billion)
23.4.10.2. Net Present Value (USD Billion)
23.4.10.3. Value Creation Analysis
23.4.11. Trodelvy
23.4.11.1. Sales Forecast (USD Billion)
23.4.11.2. Net Present Value (USD Billion)
23.4.11.3. Value Creation Analysis
23.4.12. Zynlonta
23.4.12.1. Sales Forecast (USD Billion)
23.4.12.2. Net Present Value (USD Billion)
23.4.12.3. Value Creation Analysis
23.4.13. Datopotamab Deruxtecan
23.4.13.1. Sales Forecast (USD Billion)
23.4.13.2. Net Present Value (USD Billion)
23.4.13.3. Value Creation Analysis
23.4.14. Patritumab Deruxtecan
23.4.14.1. Sales Forecast (USD Billion)
23.4.14.2. Net Present Value (USD Billion)
23.4.14.3. Value Creation Analysis
23.4.15. SHR-A1811
23.4.15.1. Sales Forecast (USD Billion)
23.4.15.2. Net Present Value (USD Billion)
23.4.15.3. Value Creation Analysis
23.4.16. SKB264
23.4.16.1. Sales Forecast (USD Billion)
23.4.16.2. Net Present Value (USD Billion)
23.4.16.3. Value Creation Analysis
23.4.17. TAA013
23.4.17.1. Sales Forecast (USD Billion)
23.4.17.2. Net Present Value (USD Billion)
23.4.17.3. Value Creation Analysis
23.4.18. Telisotuzumab Vedotin
23.4.18.1. Sales Forecast (USD Billion)
23.4.18.2. Net Present Value (USD Billion)
23.4.18.3. Value Creation Analysis
23.4.19. Trastuzumab Duocarmazine
23.4.19.1. Sales Forecast (USD Billion)
23.4.19.2. Net Present Value (USD Billion)
23.4.19.3. Value Creation Analysis
23.4.20. Tusamitamab Ravtansine
23.4.20.1. Sales Forecast (USD Billion)
23.4.20.2. Net Present Value (USD Billion)
23.4.20.3. Value Creation Analysis
23.4.21. Upifitamab Rilsodotin
23.4.21.1. Sales Forecast (USD Billion)
23.4.21.2. Net Present Value (USD Billion)
23.4.21.3. Value Creation Analysis
24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Oxford Biotherapeutics
24.2.1. Company Snapshot
24.2.2. Interview Transcript: Christian Rohlff, Founder and Chief Executive Officer
24.3. Angiex
24.3.1. Company Snapshot
24.3.2. Interview Transcript: Paul Jaminet, Founder and Chief Operating Officer
24.4. Syndivia
24.4.1. Company Snapshot
24.4.2. Interview Transcript: Sasha Koniev, Co-Founder and Chief Executive Officer
24.5. BSP Pharmaceuticals
24.5.1. Company Snapshot
24.5.2. Interview Transcript: Aldo Braca, President and Chief Executive Officer and Giorgio Salciarini, Technical Business Development Senior Manager
24.6. PolyTherics (an Abzena company)
24.6.1. Company Snapshot
24.6.2. Interview Transcript: John Burt, Former Chief Executive Officer
24.7. CureMeta
24.7.1. Company Snapshot
24.7.2. Interview Transcript: Michael Schopperle, Founder and Chief Executive Officer
24.8. CytomX Therapeutics
24.8.1. Company Snapshot
24.8.2. Interview Transcript: Jeff Landau, Chief Business Officer and Head of Strategy
24.9. NBE-Therapeutics
24.9.1. Company Snapshot
24.9.2. Interview Transcript: Wouter Verhoeven, Former Chief Business Officer
24.10. Cerbios-Pharma
24.10.1. Company Snapshot
24.10.2. Interview Transcript: Denis Angioletti, Chief Commercial Officer
24.11. Eisai
24.11.1. Company Snapshot
24.11.2. Interview Transcript: Toshimitsu Uenaka, President and Takashi Owa, Senior Vice President and Chief Scientific Officer
24.12. AbTis
24.12.1. Company Snapshot
24.12.2. Interview Transcript: Justin Oh, Chief Business Officer
24.13. AmbrX
24.13.1. Company Snapshot
24.13.2. Interview Transcript: Sukumar Sakamuri, Former Vice President and Head of Chemistry
24.14. Synaffix
24.14.1. Company Snapshot
24.14.2. Interview Transcript: Anthony DeBoer, Vice President, Business Development
24.15. Pierre Fabre
24.15.1. Company Snapshot
24.15.2. Interview Transcript: Christian Bailly, Former Director
24.16. Catalent Pharma Solutions
24.16.1. Company Snapshot
24.16.2. Interview Transcript: Jennifer L. Mitcham, Former Director, SMARTag ADCs and Bioconjugates and Stacy McDonald, Former Group Product Manager
24.17. Lonza
24.17.1. Company Snapshot
24.17.2. Interview Transcript: Laurent Ducry, Former Head of Bioconjugates Commercial Development
24.18. Piramal Healthcare
24.18.1. Company Snapshot
24.18.2. Interview Transcript: Mark Wright, Former Site Head
24.19. Ajinomoto Bio-Pharma Services
24.19.1. Company Snapshot
24.19.2. Interview Transcript: Tatsuya Okuzumi, General Manager, Business Development, CDMO Business
24.20. Cardiff University
24.20.1. Company Snapshot
24.20.2. Interview Transcript: Alan Burnett, Professor, School of Medicine
24.21. Anonymous, Director, Business Development, Leading CMO
24.22. Anonymous, Chief Executive Officer, Leading CMO
25. CONCLUSION
26. APPENDIX 1: TABULATED DATA
27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
